Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.
about
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutationsC/EBPα and MYB regulate FLT3 expression in AMLThe multifaceted functions of C/EBPα in normal and malignant haematopoiesis.The molecular basis of myeloid malignancies.Gene expression profiles associated with pediatric relapsed AML.Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.Regulation of monocyte differentiation by specific signaling modules and associated transcription factor networks.C/EBPα in normal and malignant myelopoiesis.Understanding chronic neutropenia: life is short.Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD).E6AP, an E3 ubiquitin ligase negatively regulates granulopoiesis by targeting transcription factor C/EBPα for ubiquitin-mediated proteasome degradation.Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood.Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.Human CD300C delivers an Fc receptor-γ-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition.Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.Transforming growth factor-β-stimulated clone-22 is a negative-feedback regulator of Ras / Raf signaling: Implications for tumorigenesis.The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBPα (C/EBPα-C(m))-induced myeloid leukemia.Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.Eμ/miR-125b transgenic mice develop lethal B-cell malignancies.Molecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model.Enforced expression of MIR142, a target of chromosome translocation in human B-cell tumors, results in B-cell depletion.Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment.High expression of ABCG2 induced by EZH2 disruption has pivotal roles in MDS pathogenesis.Evaluation of a Small Animal Irradiation System for Animal Experiments Using EBT3 Model GAFCHROMIC™ Film.Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
P2860
Q28590040-5103A3D8-7092-46AC-AB97-64CD2CE11D4FQ34425939-58E365C9-B4CC-4EF4-A090-299CCD798463Q34502869-35EAD42D-15A5-451B-B6E1-2687A172A8E8Q35103708-E92C6DD7-9F5C-4EE1-83D1-058E9E8DB1A6Q35302035-9E98E3C9-7EAF-4B25-9084-BE7563BEF125Q35538419-D4B4E3F3-D0FD-4B10-B6CA-771106757AE7Q37706838-6A5427BB-9920-4C0B-8632-1CE535683089Q38092683-42182ED9-2178-4E16-ACC4-DD6F16C9DCDAQ38370875-A32D57E6-D5AC-42F7-8899-03691FF33B69Q38604646-42A209F1-0224-4A7D-8FF8-04C4F99A8FBAQ38641382-1E8DE148-C451-4E8D-B31E-AB21FD6987B3Q39163990-5BD2C693-CB6F-4D49-A875-8657D12CE2CBQ39253750-85F2CDF5-5C20-487B-8EEF-3F36AA25125DQ39306735-8D249408-B380-4491-AE3A-9A6C07E16404Q39437389-2D43DD22-6B2C-43DD-9D5F-1F77E6471ED8Q41116097-A0BA35CE-8C80-4ECD-ADF4-F7C860258871Q42113668-FDB09CA1-F3CE-41F6-B284-6B3762AB6DBAQ42805287-076A105A-F19B-4A14-BAAF-89A54981485AQ43070849-C0276F92-F150-41F1-8ABC-787941373ACAQ44210348-DA084D97-5E6E-49B8-8744-03C976B604F9Q45176487-8C61EBBD-0ACF-4ADE-8B4F-F1EA4A92ECD5Q45853633-73D70259-FFFA-48B8-8D96-C47427901F7BQ45876973-A5B0FB4A-DDCA-4BAA-B362-2C6EA40A702AQ47409251-D4B5B62C-7A9F-4276-A508-E19A3BE4B9CEQ47660404-0AB52C67-1C47-424C-AAEA-601B67542137Q48106388-47705F04-A49D-458F-9984-60FA94AA547DQ50055705-1DD980C6-FE33-4E97-9489-4D1D3F9C8FAEQ50532385-5AD4BD75-052C-4D1F-B5AB-C6E1DFDB423CQ53197147-83E2F79C-AA75-4553-996E-B6C72F1A38E0
P2860
Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Two types of C/EBPα mutations ...... clinical data and BMT models.
@ast
Two types of C/EBPα mutations ...... clinical data and BMT models.
@en
type
label
Two types of C/EBPα mutations ...... clinical data and BMT models.
@ast
Two types of C/EBPα mutations ...... clinical data and BMT models.
@en
prefLabel
Two types of C/EBPα mutations ...... clinical data and BMT models.
@ast
Two types of C/EBPα mutations ...... clinical data and BMT models.
@en
P2093
P1433
P1476
Two types of C/EBPα mutations ...... clinical data and BMT models.
@en
P2093
Hideaki Nakajima
Hironori Harada
Jiro Kitaura
Katsuhiro Togami
Naoko Kato
Naoko Watanabe-Okochi
Noriko Doki
Toshihiko Oki
Toshio Kitamura
Yuka Harada
P304
P356
10.1182/BLOOD-2010-02-270181
P407
P577
2010-09-30T00:00:00Z